Nautilus Biotechnology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Nautilus Biotechnology, Inc. on June 14, 2023. The company is an emerging growth company incorporated in Delaware, with common stock trading on the Nasdaq Stock Market under the symbol NAUT.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 17, 2023), 124,866,392 shares were outstanding. 109,216,205 shares were represented at the meeting. The following matters were approved:
- Election of Class II Directors: All three nominees were elected to serve until the 2026 annual meeting.
- Ratification of Auditors: The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Attendance at the Annual Meeting represented approximately 87.5% of outstanding shares.
- Matthew McIlwain received the highest number of withheld votes among the director nominees (3,402,603).
- Broker non-votes totaled 13,665,128 shares for the director election.
- PricewaterhouseCoopers LLP received 108,805,235 votes in favor of ratification.